WISDOM
22.11.2022 12:18:41 CET | Business Wire | Press release
Wisdom, a social audio app that facilitates one-to-one meaningful conversations, today launches a pioneering new format, ‘Voice Answers’, an asynchronous short-form audio take on the traditional questions and answers format.
Voice Answers was designed to overcome the limitations associated with the live social audio format, popularised by Clubhouse. Now the centerpiece of the app, ‘Voice Answers’ delivers an algorithmically curated feed of wise answers to self-discovery questions like “Describe your idea of a perfect day.” to mentoring questions like “How do I break into the film industry?” to life hack questions like “How do I set boundaries in a relationship?”
Social Audio has demonstrated tremendous promise, with platforms like Clubhouse, Spotify, Twitter, Discord and LinkedIn rolling out social audio experiences to hundreds of millions of users. However, social audio has recently been much maligned, with recent headlines including “Is social audio already dead?” and “The Rise And Fall Of Social Audio.”
Dayo Akinrinade founder and CEO of Wisdom comments: “The biggest challenge with social audio today is its low listening value-to-word ratio. While podcasts are carefully planned and produced, social audio tends to be more freewheeling and, as a result, the content quality is less reliable. Another challenge is the consumption of live audio content being limited to whomever happens to be listening at a given time. Inspired by TikTok’s content-first algorithm and short-video format, my goal with Voice Answers' asynchronous short-form audio format, is to bring elements of TikTok’s innovation to social audio by preserving the excitement of live conversations, whilst also solving the low listening value-to-word ratio problem that's endemic to the live social audio format that Clubhouse pioneered.”
With today’s launch of Voice Answers, the Wisdom app opens to a voice answer, which the user can listen to or swipe. Each swipe informs the machine-learning algorithm, helping improve content recommendations to provide a stream of personalised, high-quality answers.
To be creator-friendly, Voice Answers are restricted to less than 60 seconds and Wisdom auto-generates an audiogram for each Voice Answer, which creators can easily share on other social networks.
Dayo continues: “Questions and answers are powerful tools to unlock insights and gain a deeper understanding of who we are and the world around us. Early in my career, as a black woman in tech, I lacked access to wise people, which hampered my progression. The Voice Answers format is positioned to empower us to share our wisdom with the world, whilst simultaneously pioneering a new short form asynchronous audio format which I hope will overcome the current challenges associated with social audio.”
Download Wisdom for Android on Google Play store here
Download Wisdom for iOS on Apple App Store here
—---- END PRESS RELEASE —--
Notes to the Editor
A selection of supporting hi-res feature images can be found on Google Drive here
About Wisdom
Wisdom is a venture-backed social audio app on a mission to leave the world a bit wiser than we found it. Wisdom connects you for live one-to-one conversations and Q&A, centered on knowledge-sharing and self-discovery. Within a year of launch, Wisdom was awarded Apple’s App Store ‘App of the Day’ twice and TechRadar’s ‘Best Android Apps of 2022’.
Wisdom is a pioneer in the social audio space having created ‘Voice Answers’ an asynchronous, short-form audio take on the traditional Q&A format, which delivers an algorithmically curated feed of high-quality voice answers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom